Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
| Autor: | Maria Palassopoulou, Christos A. Apostolopoulos, Nikolaos Harhalakis, Ioannis Batsis, A Spyridonidis, Theodoros P. Vassilakopoulos, Dimitrios Grentzelias, Maria K. Angelopoulou, Ioanna Sakellari, Maria Moschogiannis, Dimitrios Margaritis, Panagiota Giannoulia, Ioannis Apostolidis, Panayiotis Panayiotidis, Panagiotis Tsirigotis, Gerassimos A. Pangalis, Elias Poulakidas, Marie-Christine Kyrtsonis, Achilles Anagnostopoulos, Paraskevi Roussou, Eleutheria Hatzimichael, Zoi Bousiou, Georgios Vassilopoulos, Vasiliki Pappa, Konstantinos Anargyrou, Panagiotis Repousis, Konstantinos Gkirkas, Christina Kalpadakis, Maria Dimou, Eurydiki Michalis |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Immunoconjugates autologous stem cell transplantation Refractory period Gastroenterology relapsed/refractory 03 medical and health sciences 0302 clinical medicine Stable Disease Autologous stem-cell transplantation Refractory Internal medicine Original Research Articles medicine Humans Original Research Article Brentuximab vedotin Retrospective Studies Brentuximab Vedotin business.industry prognostic factors Retrospective cohort study Hematology General Medicine medicine.disease Prognosis Hodgkin Disease Survival Analysis Surgery Clinical trial Treatment Outcome Oncology 030220 oncology & carcinogenesis Female business Progressive disease Hodgkin lymphoma 030215 immunology medicine.drug |
| Zdroj: | Hematological Oncology |
| ISSN: | 1099-1069 |
| Popis: | This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty‐seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2‐16), and the median time to best response was the fourth cycle. Fifty‐seven patients achieved an objective response: twenty‐two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty‐six (27%) had progressive disease as their best response. At a median follow‐up of 11.5 months, median progression‐free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV (P = .005). Bulky disease (P = .01) and response to BV (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text